Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations

NCT05625087 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05625087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05625087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Terminated
Start date
October 19, 2023
Completion date
January 20, 2026
Enrollment
4 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer stage iv